Targeted Therapies in Oncology

Major advances have been made in key pathways that control tumor progression. This has led to the development of new anticancer agents that can block the activity of proteins involved in neoplastic cell development and proliferation. This volume provides a concise panorama of existing targeted therapies and progress into future anticancer treatments. Topics include targeted agents of immune checkpoints, signal-transduction and stem cell inhibitors, antiangiogenic and vascular-disrupting agents, apoptosis modulators, and tumor profiling for drug development. The book emphasizes the biology behind this new class of drugs and the clinical achievements obtained.

Since the last edition of this book, major advances have been made in our understanding of key pathways that control tumor progression. This has led to the development of new anticancer agents that have the ability to block the activity of proteins involved in neoplastic cell development and proliferation. Targeted Therapies in Oncology, Second Edition provides a concise timely panorama of existing targeted therapies and progress into future anticancer treatments.

These therapies notably include:

• Targeted agents of immune checkpoints











• Signal-transduction inhibitors











• Antiangiogenic agents











• Vascular-disrupting agents











• Apoptosis modulators











• Stem cell inhibitors











• Tumor profiling for drug development

The book emphasizes the biology behind this new class of drugs as well as the clinical achievements obtained. The contributors to this volume stand at the cutting edge of cancer research and treatment around the world.